Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Kyoung Min Kim  (Kim KM) 4 Articles
Clinical Diabetes & Therapeutics
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
Soo Lim, Kyoung Min Kim, Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yongsoo Park, Sang Jin Kim, Hak Chul Jang, Dong Seop Choi
Diabetes Metab J. 2017;41(5):377-385.   Published online October 24, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.5.377
  • 4,243 View
  • 42 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this multicenter, randomized, double-blind study was to examine the effect of lobeglitazone, a novel thiazolidinedione, on the changes in bone mineral density (BMD) in patients with type 2 diabetes mellitus.

Methods

A 24-week, double-blinded phase was followed by a 28-week, open-label phase, in which the placebo group also started to receive lobeglitazone. A total of 170 patients aged 34 to 76 years were randomly assigned in a 2:1 ratio to receive lobeglitazone 0.5 mg or a matching placebo orally, once daily. BMD was assessed using dual-energy X-ray absorptiometry at week 24 and at the end of the study (week 52).

Results

During the double-blinded phase, the femur neck BMD showed decreasing patterns in both groups, without statistical significance (−0.85%±0.36% and −0.78%±0.46% in the lobeglitazone and placebo groups, respectively). The treatment difference between the groups was 0.07%, which was also not statistically significant. Further, minimal, nonsignificant decreases were observed in both groups in the total hip BMD compared to values at baseline, and these differences also did not significantly differ between the groups. During the open-label phase, the BMD was further decreased, but not significantly, by −0.32% at the femur neck and by −0.60% at the total hip in the lobeglitazone group, and these changes did not significantly differ compared with the original placebo group switched to lobeglitazone.

Conclusion

Our results indicate that treatment with lobeglitazone 0.5 mg over 52 weeks showed no detrimental effect on the BMD compared to the placebo.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
    Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
  • The benefits of adipocyte metabolism in bone health and regeneration
    Lisa-Marie Burkhardt, Christian H. Bucher, Julia Löffler, Charlotte Rinne, Georg N. Duda, Sven Geissler, Tim J. Schulz, Katharina Schmidt-Bleek
    Frontiers in Cell and Developmental Biology.2023;[Epub]     CrossRef
  • Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
  • Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
    Jun Hwa Hong, Jun Sung Moon, Kayeon Seong, Soo Lim
    Diabetes Research and Clinical Practice.2023; 203: 110872.     CrossRef
  • Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study
    Nitish Khandelwal, Surbhi Rajauria, Siddhesh Pandurang Kanjalkar, Omkar Shivaji Chavanke, Sanjay Rai
    Cureus.2023;[Epub]     CrossRef
  • Lobeglitazone and Its Therapeutic Benefits: A Review
    Balamurugan M, Sarumathy S, Robinson R
    Cureus.2023;[Epub]     CrossRef
  • A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
    Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
  • A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
    Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
    Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
    Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee, Bong-Soo Cha
    Diabetes & Metabolism Journal.2021; 45(3): 326.     CrossRef
  • Effect of lobeglitazone on motor function in rat model of Parkinson’s disease with diabetes co-morbidity
    Kambiz Hassanzadeh, Arman Rahimmi, Mohammad Raman Moloudi, Rita Maccarone, Massimo Corbo, Esmael Izadpanah, Marco Feligioni
    Brain Research Bulletin.2021; 173: 184.     CrossRef
  • Recent Perspective on Thiazolidinedione
    Won Jun Kim
    The Journal of Korean Diabetes.2021; 22(2): 97.     CrossRef
  • Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models
    Sabrina Ehnert, Helen Rinderknecht, Romina H. Aspera-Werz, Victor Häussling, Andreas K. Nussler
    Archives of Toxicology.2020; 94(12): 3937.     CrossRef
  • Update on: effects of anti-diabetic drugs on bone metabolism
    Guillaume Mabilleau, Béatrice Bouvard
    Expert Review of Endocrinology & Metabolism.2020; 15(6): 415.     CrossRef
  • The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta‐analysis of observational studies
    Khemayanto Hidayat, Xuan Du, Meng‐Jiao Wu, Bi‐Min Shi
    Obesity Reviews.2019; 20(10): 1494.     CrossRef
  • Diabetes pharmacotherapy and effects on the musculoskeletal system
    Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu, Kathryn M. Thrailkill
    Diabetes/Metabolism Research and Reviews.2019;[Epub]     CrossRef
  • Morin Exerts Anti‐Arthritic Effects by Attenuating Synovial Angiogenesis via Activation of Peroxisome Proliferator Activated Receptor‐γ
    Mengfan Yue, Ni Zeng, Yufeng Xia, Zhifeng Wei, Yue Dai
    Molecular Nutrition & Food Research.2018;[Epub]     CrossRef
  • The effects of diabetes therapy on bone: A clinical perspective
    Karim G. Kheniser, Carmen M. Polanco Santos, Sangeeta R. Kashyap
    Journal of Diabetes and its Complications.2018; 32(7): 713.     CrossRef
  • Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
    Da Young Lee, Ji A Seo
    Diabetes & Metabolism Journal.2017; 41(5): 374.     CrossRef
Epidemiology
Application of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline to the Korean National Health and Nutrition Examination Surveys from 1998 to 2012
Young Shin Song, Tae Jung Oh, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang, Kyong Soo Park, Soo Lim
Diabetes Metab J. 2017;41(1):38-50.   Published online December 16, 2016
DOI: https://doi.org/10.4093/dmj.2017.41.1.38
  • 4,246 View
  • 29 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the treatment of blood cholesterol recommends statin therapy for individuals at high risk of atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to investigate serial trends in the percentages of Korean adults considered eligible for statin therapy according to the new ACC/AHA cholesterol guideline.

Methods

Data from the Korean National Health and Nutrition Examination Survey (KNHANES) I (1998, n=7,698), II (2001, n=5,654), III (2005, n=5,269), IV (2007 to 2009, n=15,727), and V (2010 to 2012, n=16,304), which used a stratified, multistage, probability sampling design, were used as representative of the entire Korean population.

Results

The percentage of adults eligible for statin therapy according to the ACC/AHA cholesterol guideline increased with time: 17.0%, 19.0%, 20.8%, 20.2%, and 22.0% in KNHANES I, II, III, IV, and V, respectively (P=0.022). The prevalence of ASCVD was 1.4% in KNHANES I and increased to 3.3% in KNHANES V. The percentage of diabetic patients aged 40 to 75 years with a low density lipoprotein cholesterol levels of 70 to 189 mg/dL increased from 4.8% in KNHANES I to 6.1% in KNHANES V. People with an estimated 10-year ASCVD risk ≥7.5% and aged 40 to 75 years accounted for the largest percentage among the four statin benefit groups: 9.1% in KNHANES I and 11.0% in KNHANES V.

Conclusion

Application of the 2013 ACC/AHA guideline has found that the percentage of Korean adults in the statin benefit groups has increased over the past 15 years.

Citations

Citations to this article as recorded by  
  • Sex differences in risk factors for subclinical hypothyroidism
    Jeonghoon Ha, Jeongmin Lee, Kwanhoon Jo, Dong-Jun Lim, Moo Il Kang, Bong Yun Cha, Min-Hee Kim
    Endocrine Connections.2018; 7(4): 511.     CrossRef
Clinical Care/Education
Hyperglycemia Is Associated with Impaired Muscle Quality in Older Men with Diabetes: The Korean Longitudinal Study on Health and Aging
Ji Won Yoon, Yong-Chan Ha, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Soo Lim, Young Joo Park, Jae Young Lim, Ki Woong Kim, Kyong Soo Park, Hak Chul Jang
Diabetes Metab J. 2016;40(2):140-146.   Published online March 31, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.2.140
  • 7,279 View
  • 77 Download
  • 86 Web of Science
  • 89 Crossref
AbstractAbstract PDFPubReader   
Background

The study aimed to investigate the influence of hyperglycemia on muscle quality in older men with type 2 diabetes.

Methods

This was a subsidiary study of the Korean Longitudinal Study of Health and Aging. Among 326 older men consenting to tests of body composition and muscle strength, 269 men were ultimately analyzed after the exclusion because of stroke (n=30) and uncertainty about the diagnosis of diabetes (n=27). Body composition was measured using dual-energy X-ray absorptiometry and computed tomography. Muscle strength for knee extension was measured using an isokinetic dynamometer. Muscle quality was assessed from the ratio of leg strength to the entire corresponding leg muscle mass.

Results

The muscle mass, strength, and quality in patients with type 2 diabetes did not differ significantly from controls. However, when patients with diabetes were subdivided according to their glycemic control status, patients with a glycosylated hemoglobin (HbA1c) level of ≥8.5% showed significantly decreased leg muscle quality by multivariate analysis (odds ratio, 4.510; P=0.045) after adjustment for age, body mass index, smoking amount, alcohol consumption, physical activity, and duration of diabetes. Physical performance status was also impaired in subjects with an HbA1c of ≥8.5%.

Conclusion

Poor glycemic control in these older patients with diabetes was associated with significant risk of decreased muscle quality and performance status. Glycemic control with an HbA1c of <8.5% might be needed to reduce the risk of adverse skeletal and functional outcomes in this population.

Citations

Citations to this article as recorded by  
  • Downhill running and caloric restriction attenuate insulin resistance associated skeletal muscle atrophy via the promotion of M2-like macrophages through TRIB3-AKT pathway
    Wei Luo, Yue Zhou, Qiang Tang, Yuhang Wang, Yansong Liu, Lei Ai
    Free Radical Biology and Medicine.2024; 210: 271.     CrossRef
  • Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
    Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
    Reviews in Endocrine and Metabolic Disorders.2024;[Epub]     CrossRef
  • Dynapenia and sarcopenia: association with the diagnosis, duration and complication of type 2 diabetes mellitus in ELSA-Brasil
    Débora Noara Duarte dos Santos, Carolina Gomes Coelho, Maria de Fátima Haueisen Sander Diniz, Bruce Bartholow Duncan, Maria Inês Schmidt, Isabela Judith Martins Bensenor, Claudia Szlejf, Rosa Weiss Telles, Sandhi Maria Barreto
    Cadernos de Saúde Pública.2024;[Epub]     CrossRef
  • Breaking Down Cachexia: A Narrative Review on the Prevalence of Cachexia in Cancer Patients and Its Associated Risk Factors
    Mahmathi Karuppannan, Fares M. S. Muthanna, Fazlin Mohd Fauzi
    Nutrition and Cancer.2024; 76(5): 404.     CrossRef
  • Mechanism of muscle atrophy in a normal-weight rat model of type 2 diabetes established by using a soft-pellet diet
    Sayaka Akieda-Asai, Hao Ma, Wanxin Han, Junko Nagata, Fumitake Yamaguchi, Yukari Date
    Scientific Reports.2024;[Epub]     CrossRef
  • Morphological and functional changes in skeletal muscle in type 2 diabetes mellitus: A systematic review and meta-analysis
    Jardeson Rocha Filgueiras, Cleudiane Pereira Sales, Ivanilson Gomes da Silva, Cristiana Maria Dos Santos, Elias de Carvalho Magalhães Neto, Rebeca Barbosa da Rocha, Vinicius Saura Cardoso
    Physiotherapy Theory and Practice.2023; 39(9): 1789.     CrossRef
  • Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy
    Dongmei Fan, Yue Wang, Bowei Liu, Fuzai Yin
    Journal of the Chinese Medical Association.2023; 86(2): 166.     CrossRef
  • Mechanisms underlying altered neuromuscular function in people with DPN
    Antonin Le Corre, Nathan Caron, Nicolas A. Turpin, Georges Dalleau
    European Journal of Applied Physiology.2023; 123(7): 1433.     CrossRef
  • Effects of body compositions on the associations between ferritin and diabetes parameters among Japanese community dwellers
    Kyi Mar Wai, Rei Akuzawa, Yoko Umeda, Wataru Munakata, Yoshiko Takahashi, Shigeyuki Nakaji, Kazushige Ihara
    Journal of Trace Elements in Medicine and Biology.2023; 78: 127174.     CrossRef
  • Effects of glycemic control on frailty: a multidimensional perspective
    Ahmed H Abdelhafiz
    Hospital Practice.2023; 51(3): 124.     CrossRef
  • Hand grip strength is inversely associated with total daily insulin dose requirement in patients with type 2 diabetes mellitus: a cross-sectional study
    Da-shuang Chen, Yun-qing Zhu, Wen-ji Ni, Yu-jiao Li, Guo-ping Yin, Zi-yue Shao, Jian Zhu
    PeerJ.2023; 11: e15761.     CrossRef
  • Sarcopenia in Type 2 Diabetes Mellitus: Study of the Modifiable Risk Factors Involved
    Surapaneni Lakshmi Sravya, Jayshree Swain, Abhay Kumar Sahoo, Swayamsidha Mangaraj, Jayabhanu Kanwar, Pooja Jadhao, Srijit Das
    Journal of Clinical Medicine.2023; 12(17): 5499.     CrossRef
  • Salbutamol ameliorates skeletal muscle wasting and inflammatory markers in streptozotocin (STZ)-induced diabetic rats
    Anand Kumar, Priyanka Prajapati, Vinit Raj, Seong-Cheol Kim, Vikas Mishra, Chaitany Jayprakash Raorane, Ritu Raj, Dinesh Kumar, Sapana Kushwaha
    International Immunopharmacology.2023; 124: 110883.     CrossRef
  • Decreased serum musclin concentration is independently associated with the high prevalence of sarcopenia in Chinese middle‐elderly patients with type 2 diabetes mellitus
    Lei Fu, Qing Zhang, Juan Liu, Xiaoqing Yuan, Xinhua Ye
    Journal of Diabetes Investigation.2023; 14(12): 1412.     CrossRef
  • Association between relative muscle strength and hypertension in middle-aged and older Chinese adults
    Jin-hua Luo, Tu-ming Zhang, Lin-lin Yang, Yu-ying Cai, Yu Yang
    BMC Public Health.2023;[Epub]     CrossRef
  • Diabetes Mellitus in the Elderly Adults in Korea: Based on Data from the Korea National Health and Nutrition Examination Survey 2019 to 2020
    Seung-Hyun Ko, Kyung Do Han, Yong-Moon Park, Jae-Seung Yun, Kyuho Kim, Jae-Hyun Bae, Hyuk-Sang Kwon, Nan-Hee Kim
    Diabetes & Metabolism Journal.2023; 47(5): 643.     CrossRef
  • Management of Hyperglycemia in Older Adults with Type 2 Diabetes
    Gunjan Y. Gandhi, Arshag D. Mooradian
    Drugs & Aging.2022; 39(1): 39.     CrossRef
  • Deleterious Effect of High-Fat Diet on Skeletal Muscle Performance Is Prevented by High-Protein Intake in Adult Rats but Not in Old Rats
    Eleonora Poggiogalle, Fanny Rossignon, Aude Carayon, Fréderic Capel, Jean-Paul Rigaudière, Sarah De Saint Vincent, Olivier Le-Bacquer, Jérôme Salles, Christophe Giraudet, Véronique Patrac, Patrice Lebecque, Stéphane Walrand, Yves Boirie, Vincent Martin, C
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Metabolic phenotypes explain the relationship between dysglycaemia and frailty in older people with type 2 diabetes
    A.H. Abdelhafiz, A.J. Sinclair
    Journal of Diabetes and its Complications.2022; 36(4): 108144.     CrossRef
  • Altered features of body composition in older adults with type 2 diabetes and prediabetes compared with matched controls
    Kirsten E. Bell, Michael T. Paris, Egor Avrutin, Marina Mourtzakis
    Journal of Cachexia, Sarcopenia and Muscle.2022; 13(2): 1087.     CrossRef
  • A modern approach to glucose-lowering therapy in frail older people with type 2 diabetes mellitus
    Ahmed H. Abdelhafiz, Daniel Pennells, Alan J. Sinclair
    Expert Review of Endocrinology & Metabolism.2022; 17(2): 95.     CrossRef
  • Metabolic syndrome and its association with components of sarcopenia in older community-dwelling Chinese
    Qiangwei Tong, Xiao Wang, Yunlu Sheng, Shu Chen, Bin Lai, Rong Lv, Jing Yu
    The Journal of Biomedical Research.2022; 36(2): 120.     CrossRef
  • Sarcopenia is associated with the Geriatric Nutritional Risk Index in elderly patients with poorly controlled type 2 diabetes mellitus
    Shun Matsuura, Koji Shibazaki, Reiko Uchida, Yukiko Imai, Takuya Mukoyama, Shoko Shibata, Hiroshi Morita
    Journal of Diabetes Investigation.2022; 13(8): 1366.     CrossRef
  • Increased serum levels of advanced glycation end products are negatively associated with relative muscle strength in patients with type 2 diabetes mellitus
    Tsung-Hui Wu, Shiow-Chwen Tsai, Hsuan-Wei Lin, Chiao-Nan Chen, Chii-Min Hwu
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Clinical outcomes of multidimensional association of type 2 diabetes mellitus, COVID-19 and sarcopenia: an algorithm and scoping systematic evaluation
    Anmar Al-Taie, Oritsetimeyin Arueyingho, Jalal Khoshnaw, Abdul Hafeez
    Archives of Physiology and Biochemistry.2022; : 1.     CrossRef
  • Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype
    Alan J. Sinclair, Daniel Pennells, Ahmed H. Abdelhafiz
    Aging Clinical and Experimental Research.2022; 34(9): 1949.     CrossRef
  • Insulin in Frail, Older People with Type 2 Diabetes—Low Threshold for Therapy
    Ahmed Abdelhafiz, Shail Bisht, Iva Kovacevic, Daniel Pennells, Alan Sinclair
    Diabetology.2022; 3(2): 369.     CrossRef
  • Sex-Specific Associations Between Low Muscle Mass and Glucose Fluctuations in Patients With Type 2 Diabetes Mellitus
    Xiulin Shi, Wenjuan Liu, Lulu Zhang, Fangsen Xiao, Peiying Huang, Bing Yan, Yiping Zhang, Weijuan Su, Qiuhui Jiang, Mingzhu Lin, Wei Liu, Xuejun Li
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Lifestyle factors associated with muscle quality in community‐dwelling older people with type 2 diabetes in Japan and Taiwan: a cross‐sectional study
    Yuko Yamaguchi, Chieko Greiner, Shu‐Chun Lee, Hirochika Ryuno, Hsin‐Yen Yen, Chiou‐Fen Lin, Ting‐I Lee, Pi‐Hsia Lee
    Psychogeriatrics.2022; 22(5): 736.     CrossRef
  • Relationship between Echo Intensity of Vastus Lateralis and Knee Extension Strength in Patients with Type 2 Diabetes Mellitus
    Yoshikazu HIRASAWA, Ryosuke MATSUKI, Hideaki TANINA
    Physical Therapy Research.2022; 25(3): 113.     CrossRef
  • Time trends (2012–2020) in glycated hemoglobin and adherence to the glycemic targets recommended for elderly patients by the Japan Diabetes Society/Japan Geriatrics Society Joint Committee among memory clinic patients with diabetes mellitus
    Taiki Sugimoto, Hisashi Noma, Yujiro Kuroda, Nanae Matsumoto, Kazuaki Uchida, Yoshinobu Kishino, Naoki Saji, Shumpei Niida, Takashi Sakurai
    Journal of Diabetes Investigation.2022; 13(12): 2038.     CrossRef
  • Relationship between Diabetes Status and Sarcopenia in Community-Dwelling Older Adults
    Kazuhei Nishimoto, Takehiko Doi, Kota Tsutsumimoto, Sho Nakakubo, Satoshi Kurita, Yuto Kiuchi, Hiroyuki Shimada
    Journal of the American Medical Directors Association.2022; 23(10): 1718.e7.     CrossRef
  • Low relative hand grip strength is associated with a higher risk for diabetes and impaired fasting glucose among the Korean population
    Min Jin Lee, Ah Reum Khang, Dongwon Yi, Yang Ho Kang, Giacomo Pucci
    PLOS ONE.2022; 17(10): e0275746.     CrossRef
  • Association between Lower-to-Upper Ratio of Appendicular Skeletal Muscle and Metabolic Syndrome
    Hyun Eui Moon, Tae Sic Lee, Tae-Ha Chung
    Journal of Clinical Medicine.2022; 11(21): 6309.     CrossRef
  • Association of plasma brain-derived neurotrophic factor levels and frailty in community-dwelling older adults
    Eun Roh, Soon Young Hwang, Eyun Song, Min Jeong Park, Hye Jin Yoo, Sei Hyun Baik, Miji Kim, Chang Won Won, Kyung Mook Choi
    Scientific Reports.2022;[Epub]     CrossRef
  • Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise
    Giulia Minniti, Letícia Maria Pescinini-Salzedas, Guilherme Almeida dos Santos Minniti, Lucas Fornari Laurindo, Sandra Maria Barbalho, Renata Vargas Sinatora, Lance Alan Sloan, Rafael Santos de Argollo Haber, Adriano Cressoni Araújo, Karina Quesada, Jesse
    International Journal of Molecular Sciences.2022; 23(21): 13452.     CrossRef
  • Multimorbidity, Frailty and Diabetes in Older People–Identifying Interrelationships and Outcomes
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Journal of Personalized Medicine.2022; 12(11): 1911.     CrossRef
  • Determinants of High-Dose Insulin Usage and Upper Extremity Muscle Strength in Adult Patients With Type 2 Diabetes
    Eren Imre, Tugce Apaydin, Hatice Gizem Gunhan, Dilek Gogas Yavuz
    Canadian Journal of Diabetes.2021; 45(4): 341.     CrossRef
  • Glycemic Control and Insulin Improve Muscle Mass and Gait Speed in Type 2 Diabetes: The MUSCLES-DM Study
    Ken Sugimoto, Hiroshi Ikegami, Yasunori Takata, Tomohiro Katsuya, Masahiro Fukuda, Hiroshi Akasaka, Yasuharu Tabara, Haruhiko Osawa, Yoshihisa Hiromine, Hiromi Rakugi
    Journal of the American Medical Directors Association.2021; 22(4): 834.     CrossRef
  • A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors
    Anna Izzo, Elena Massimino, Gabriele Riccardi, Giuseppe Della Pepa
    Nutrients.2021; 13(1): 183.     CrossRef
  • Decreased handgrip strength in patients with type 2 diabetes: A cross-sectional study in a tertiary care hospital in north India
    Parjeet Kaur, Ritesh Bansal, Bharti Bhargava, Sunil Mishra, Harmandeep Gill, Ambrish Mithal
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 325.     CrossRef
  • Factors associated with relative muscle strength in patients with type 2 diabetes mellitus
    Chiao-Nan Chen, Ting-Chung Chen, Shiow-Chwen Tsai, Chii-Min Hwu
    Archives of Gerontology and Geriatrics.2021; 95: 104384.     CrossRef
  • Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people
    Demelza Emmerton, Ahmed Abdelhafiz
    Hospital Practice.2021; 49(3): 164.     CrossRef
  • Influence of glucose, insulin fluctuation, and glycosylated hemoglobin on the outcome of sarcopenia in patients with type 2 diabetes mellitus
    Yuxi Lin, Yongze Zhang, Ximei Shen, Lingning Huang, Sunjie Yan
    Journal of Diabetes and its Complications.2021; 35(6): 107926.     CrossRef
  • Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
    Gregory Habig, Christa Smaltz, Dina Halegoua-DeMarzio
    Metabolites.2021; 11(4): 242.     CrossRef
  • Sensory-Motor Mechanisms Increasing Falls Risk in Diabetic Peripheral Neuropathy
    Neil D. Reeves, Giorgio Orlando, Steven J. Brown
    Medicina.2021; 57(5): 457.     CrossRef
  • Impact of frailty metabolic phenotypes on the management of older people with type 2 diabetes mellitus
    Ahmed H Abdelhafiz, Demelza Emmerton, Alan J Sinclair
    Geriatrics & Gerontology International.2021; 21(8): 614.     CrossRef
  • Type 2 diabetes mellitus in older adults: clinical considerations and management
    Srikanth Bellary, Ioannis Kyrou, James E. Brown, Clifford J. Bailey
    Nature Reviews Endocrinology.2021; 17(9): 534.     CrossRef
  • Metabolic Syndrome and Sarcopenia
    Hiroki Nishikawa, Akira Asai, Shinya Fukunishi, Shuhei Nishiguchi, Kazuhide Higuchi
    Nutrients.2021; 13(10): 3519.     CrossRef
  • Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia
    Jeffrey Kingsley, Keiichi Torimoto, Tomoki Hashimoto, Satoru Eguchi
    Clinical Science.2021; 135(21): 2503.     CrossRef
  • Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study
    Bo Kyung Koo, Seoil Moon, Min Kyong Moon
    BMC Geriatrics.2021;[Epub]     CrossRef
  • Associations between homocysteine, inflammatory cytokines and sarcopenia in Chinese older adults with type 2 diabetes
    Zhi-Jing Mu, Jun-Ling Fu, Li-Na Sun, Piu Chan, Shuang-Ling Xiu
    BMC Geriatrics.2021;[Epub]     CrossRef
  • The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies
    Yu-Shun Qiao, Yin-He Chai, Hong-Jian Gong, Zhiyessova Zhuldyz, Coen D. A. Stehouwer, Jian-Bo Zhou, Rafael Simó
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • The utility of the ultrasonographic assessment of the lower leg muscles to evaluate sarcopenia and muscle quality in older adults
    Masaaki Isaka, Ken Sugimoto, Taku Fujimoto, Yukiko Yasunobe, Keyu Xie, Yuri Onishi, Shino Yoshida, Toshimasa Takahashi, Hitomi Kurinami, Hiroshi Akasaka, Yasushi Takeya, Koichi Yamamoto, Hiromi Rakugi
    JCSM Clinical Reports.2021; 6(2): 53.     CrossRef
  • Associations between grip strength and glycemic control in type 2 diabetes mellitus: an analysis of data from the 2014-2019 Korea National Health and Nutrition Examination Survey
    Harim Choe, Hoyong Sung, Geon Hui Kim, On Lee, Hyo Youl Moon, Yeon Soo Kim
    Epidemiology and Health.2021; 43: e2021080.     CrossRef
  • Uncontrolled Diabetes as an Associated Factor with Dynapenia in Adults Aged 50 Years or Older: Sex Differences
    Clarice Cavalero Nebuloni, Roberta de Oliveira Máximo, Cesar de Oliveira, Tiago da Silva Alexandre, Anne Newman
    The Journals of Gerontology: Series A.2020; 75(6): 1191.     CrossRef
  • Identification and prevalence of frailty in diabetes mellitus and association with clinical outcomes: a systematic review protocol
    Peter Hanlon, Isabella Fauré, Neave Corcoran, Elaine Butterly, Jim Lewsey, David A McAllister, Frances S Mair
    BMJ Open.2020; 10(9): e037476.     CrossRef
  • Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study
    Uta Ferrari, Cornelia Then, Marietta Rottenkolber, Canan Selte, Jochen Seissler, Romy Conzade, Birgit Linkohr, Annette Peters, Michael Drey, Barbara Thorand
    Acta Diabetologica.2020; 57(9): 1057.     CrossRef
  • Triad of impairment in older people with diabetes-reciprocal relations and clinical implications
    A.H. Abdelhafiz, P.C. Davies, A.J. Sinclair
    Diabetes Research and Clinical Practice.2020; 161: 108065.     CrossRef
  • Physical activity and exercise: Strategies to manage frailty
    Javier Angulo, Mariam El Assar, Alejandro Álvarez-Bustos, Leocadio Rodríguez-Mañas
    Redox Biology.2020; 35: 101513.     CrossRef
  • Handgrip measurement as a useful benchmark for locomotive syndrome in patients with type 2 diabetes mellitus: A KAMOGAWA‐DM cohort study
    Noriyuki Kitagawa, Takuro Okamura, Nobuko Kitagawa, Yoshitaka Hashimoto, Masahide Hamaguchi, Michiaki Fukui
    Journal of Diabetes Investigation.2020; 11(6): 1602.     CrossRef
  • Edmonton frail score is associated with diabetic control in elderly type 2 diabetic subjects
    Satilmis Bilgin, Gulali Aktas, Ozge Kurtkulagi, Burcin M. Atak, Tuba T. Duman
    Journal of Diabetes & Metabolic Disorders.2020; 19(1): 511.     CrossRef
  • Comparison of field- and laboratory-based estimates of muscle quality index between octogenarians and young older adults: an observational study
    Dahan da Cunha Nascimento, Jonato Prestes, Joyce de Sousa Diniz, Pedro Rodrigues Beal, Vicente Paulo Alves, Whitley Stone, Fabiani Lage Rodrigues Beal
    Journal of Exercise Rehabilitation.2020; 16(5): 458.     CrossRef
  • Tip 2 Diyabetli Hastalarda Kan Glukoz Seviyesi ile Kas Gücü, Propriosepsiyon ve Vücut Kompozisyonu Arasındaki İlişki
    Zahide Betül TAYFUR, Esra ATILGAN
    Turkish Journal of Diabetes and Obesity.2020; 4(3): 207.     CrossRef
  • Challenges and Strategies for Diabetes Management in Community-Living Older Adults
    Alan J. Sinclair, Ahmed H. Abdelhafiz
    Diabetes Spectrum.2020; 33(3): 217.     CrossRef
  • Association between deterioration in muscle strength and peripheral neuropathy in people with diabetes
    Tae Jung Oh, Sunyoung Kang, Jie-Eun Lee, Jae Hoon Moon, Sung Hee Choi, Soo Lim, Hak Chul Jang
    Journal of Diabetes and its Complications.2019; 33(8): 598.     CrossRef
  • The Association between Body Composition using Dual energy X-ray Absorptiometry and Type-2 Diabetes: A Systematic Review and Meta-Analysis of Observational studies
    Preeti Gupta, Carla Lanca, Alfred T. L. Gan, Pauline Soh, Sahil Thakur, Yijin Tao, Neelam Kumari, Ryan E. K. Man, Eva K. Fenwick, Ecosse L. Lamoureux
    Scientific Reports.2019;[Epub]     CrossRef
  • MECHANISMS OF ENDOCRINE DISEASE: Sarcopenia in endocrine and non-endocrine disorders
    Victoria Zeghbi Cochenski Borba, Tatiana Lemos Costa, Carolina Aguiar Moreira, Cesar Luiz Boguszewski
    European Journal of Endocrinology.2019; 180(5): R185.     CrossRef
  • Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
    Yu Hirata, Kazuhiro Nomura, Yoko Senga, Yuko Okada, Kenta Kobayashi, Shiki Okamoto, Yasuhiko Minokoshi, Michihiro Imamura, Shin’ichi Takeda, Tetsuya Hosooka, Wataru Ogawa
    JCI Insight.2019;[Epub]     CrossRef
  • Hyperglycemia in non‐obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus
    Ken Sugimoto, Yasuharu Tabara, Hiroshi Ikegami, Yasunori Takata, Kei Kamide, Tome Ikezoe, Eri Kiyoshige, Yukako Makutani, Hiroshi Onuma, Yasuyuki Gondo, Kazunori Ikebe, Noriaki Ichihashi, Tadao Tsuboyama, Fumihiko Matsuda, Katsuhiko Kohara, Mai Kabayama,
    Journal of Diabetes Investigation.2019; 10(6): 1471.     CrossRef
  • Diabetic Peripheral Neuropathy as a Risk Factor for Sarcopenia
    Tae Jung Oh, Yoojung Song, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
    Annals of Geriatric Medicine and Research.2019; 23(4): 170.     CrossRef
  • Diabetes and frailty
    Mariam El Assar, Olga Laosa, Leocadio Rodríguez Mañas
    Current Opinion in Clinical Nutrition & Metabolic Care.2019; 22(1): 52.     CrossRef
  • Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus
    Noriko Ogama, Takashi Sakurai, Shuji Kawashima, Takahisa Tanikawa, Haruhiko Tokuda, Shosuke Satake, Hisayuki Miura, Atsuya Shimizu, Manabu Kokubo, Shumpei Niida, Kenji Toba, Hiroyuki Umegaki, Masafumi Kuzuya
    Journal of Clinical Medicine.2019; 8(3): 319.     CrossRef
  • Diabetes in the elderly
    Ahmed H. Abdelhafiz, Alan J. Sinclair
    Medicine.2019; 47(2): 119.     CrossRef
  • Diabetes and Muscle Dysfunction in Older Adults
    Hak Chul Jang
    Annals of Geriatric Medicine and Research.2019; 23(4): 160.     CrossRef
  • Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people
    C.E. Hambling, K. Khunti, X. Cos, J. Wens, L. Martinez, P. Topsever, S. Del Prato, A. Sinclair, G. Schernthaner, G. Rutten, S. Seidu
    Primary Care Diabetes.2019; 13(4): 330.     CrossRef
  • Effects of resistance training on neuromuscular parameters in elderly with type 2 diabetes mellitus: A randomized clinical trial
    Cíntia E. Botton, Daniel Umpierre, Anderson Rech, Lucinéia O. Pfeifer, Carlos L.F. Machado, Juliana L. Teodoro, Alexandre S. Dias, Ronei S. Pinto
    Experimental Gerontology.2018; 113: 141.     CrossRef
  • Management of Elderly Diabetes Patients Who Are Unable to Self-Care
    Bok Rye Song
    The Journal of Korean Diabetes.2018; 19(4): 232.     CrossRef
  • Decreased Muscle Strength and Quality in Diabetes-Related Dementia
    Akito Tsugawa, Yusuke Ogawa, Naoto Takenoshita, Yoshitsugu Kaneko, Hirokuni Hatanaka, Eriko Jaime, Raita Fukasawa, Haruo Hanyu
    Dementia and Geriatric Cognitive Disorders Extra.2017; 7(3): 454.     CrossRef
  • Diabetes and Sarcopenia
    Dong Hyun Kim, Tae Yang Yu
    The Journal of Korean Diabetes.2017; 18(4): 239.     CrossRef
  • Frailty and sarcopenia - newly emerging and high impact complications of diabetes
    Alan J. Sinclair, Ahmed H. Abdelhafiz, Leocadio Rodríguez-Mañas
    Journal of Diabetes and its Complications.2017; 31(9): 1465.     CrossRef
  • Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study
    Tatsuya Fukuda, Ryotaro Bouchi, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa
    BMJ Open Diabetes Research & Care.2017; 5(1): e000404.     CrossRef
  • Practical considerations for managing patients with diabetes and dementia
    Michelle L Mair, Rohin Athavale, Ahmed H Abdelhafiz
    Expert Review of Endocrinology & Metabolism.2017; 12(6): 429.     CrossRef
  • Sarcopenia: An Endocrine Disorder?
    Alexis McKee, John E. Morley, Alvin M. Matsumoto, Aaron Vinik
    Endocrine Practice.2017; 23(9): 1143.     CrossRef
  • Response: Hyperglycemia Is Associated with Impaired Muscle Quality in Older Men with Diabetes: The Korean Longitudinal Study on Health and Aging (Diabetes Metab J 2016;40:140-6)
    Ji Won Yoon, Hak Chul Jang
    Diabetes & Metabolism Journal.2016; 40(3): 250.     CrossRef
  • Salivary lactate dehydrogenase and aminotransferases in diabetic patients
    Barbara Malicka, Katarzyna Skoskiewicz-Malinowska, Urszula Kaczmarek
    Medicine.2016; 95(47): e5211.     CrossRef
  • Explanatory models of muscle performance in acromegaly patients evaluated by knee isokinetic dynamometry: Implications for rehabilitation
    Agnaldo José Lopes, Arthur Sá Ferreira, Evelyn Mendes Walchan, Mauricio Santos Soares, Priscila Santos Bunn, Fernando Silva Guimarães
    Human Movement Science.2016; 49: 160.     CrossRef
  • Letter: Hyperglycemia Is Associated with Impaired Muscle Quality in Older Men with Diabetes: The Korean Longitudinal Study on Health and Aging (Diabetes Metab J 2016;40:140-6)
    Jun Sung Moon
    Diabetes & Metabolism Journal.2016; 40(3): 248.     CrossRef
  • Sarcopenia, Frailty, and Diabetes in Older Adults
    Hak Chul Jang
    Diabetes & Metabolism Journal.2016; 40(3): 182.     CrossRef
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass
Kyong Yeun Jung, Kyoung Min Kim, Soo Lim
Diabetes Metab J. 2014;38(6):426-436.   Published online December 15, 2014
DOI: https://doi.org/10.4093/dmj.2014.38.6.426
  • 6,097 View
  • 115 Download
  • 20 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   

The goal for the treatment of patients with diabetes has today shifted from merely reducing glucose concentrations to preventing the natural decline in β-cell function and delay the progression of disease. Pancreatic β-cell dysfunction and decreased β-cell mass are crucial in the development of diabetes. The β-cell defects are the main pathogenesis in patients with type 1 diabetes and are associated with type 2 diabetes as the disease progresses. Recent studies suggest that human pancreatic β-cells have a capacity for increased proliferation according to increased demands for insulin. In humans, β-cell mass has been shown to increase in patients showing insulin-resistance states such as obesity or in pregnancy. This capacity might be useful for identifying new therapeutic strategies to reestablish a functional β-cell mass. In this context, therapeutic approaches designed to increase β-cell mass might prove a significant way to manage diabetes and prevent its progression. This review describes the various β-cell defects that appear in patients with diabetes and outline the mechanisms of β-cell failure. We also review common methods for assessing β-cell function and mass and methodological limitations in vivo. Finally, we discuss the current therapeutic approaches to improve β-cell function and increase β-cell mass.

Citations

Citations to this article as recorded by  
  • Polychlorinated biphenyls exposure and type 2 diabetes: Molecular mechanism that causes insulin resistance and islet damage
    Qiuli Shan, Jingyu Liu, Fan Qu, Anhui Chen, Wenxing He
    Environmental Toxicology.2024; 39(4): 2466.     CrossRef
  • Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
    Laure Sayyed Kassem, Aman Rajpal, Margarita Victoria Barreiro, Faramarz Ismail‐Beigi
    Journal of Diabetes.2023; 15(10): 817.     CrossRef
  • Preliminary Evaluation of Potential Properties of Three Probiotics and Their Combination with Prebiotics on GLP-1 Secretion and Type 2 Diabetes Alleviation
    Ran Xiao, Ran Wang, Shusen Li, Xiaohong Kang, Yimei Ren, Erna Sun, Chenyuan Wang, Jingjing He, Jing Zhan, Wen Yi Kang
    Journal of Food Quality.2022; 2022: 1.     CrossRef
  • Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements
    Muhammad Fauzi, Takaaki Murakami, Hiroyuki Fujimoto, Ainur Botagarova, Kentaro Sakaki, Sakura Kiyobayashi, Masahito Ogura, Nobuya Inagaki
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
    Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
    Phytomedicine.2019; 62: 152946.     CrossRef
  • The Potential of Hibiscus sabdariffa Linn in Inducing Glucagon-Like Peptide-1 via SGLT-1 and GLPR in DM Rats
    Neng Tine Kartinah, Fadilah Fadilah, Ermita Ilyas Ibrahim, Yuliana Suryati
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Efficacy of short‑term intensive treatment with insulin pump to improve islet β‑cell function in newly diagnosed type 2 diabetes via inhibition of oxidative stress
    Hai‑Tong Liu, Yan Gao
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
    Angelo Avogaro, Elías Delgado, Ildiko Lingvay
    Diabetes/Metabolism Research and Reviews.2018;[Epub]     CrossRef
  • Metformin prevents glucotoxicity by alleviating oxidative and ER stress–induced CD36 expression in pancreatic beta cells
    Jun Sung Moon, Udayakumar Karunakaran, Suma Elumalai, In-Kyu Lee, Hyoung Woo Lee, Yong-Woon Kim, Kyu Chang Won
    Journal of Diabetes and its Complications.2017; 31(1): 21.     CrossRef
  • The variability in beta‐cell function in placebo‐treated subjects with type 2 diabetes: application of the weight‐HbA1c‐insulin‐glucose (WHIG) model
    Janna K. Duong, Willem de Winter, Steve Choy, Nele Plock, Himanshu Naik, Walter Krauwinkel, Sandra A.G. Visser, Katia M. Verhamme, Miriam C. Sturkenboom, B.H. Stricker, Meindert Danhof
    British Journal of Clinical Pharmacology.2017; 83(3): 487.     CrossRef
  • Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling
    Bethany A. Carboneau, Richard M. Breyer, Maureen Gannon
    Journal of Cell Communication and Signaling.2017; 11(2): 105.     CrossRef
  • Effects of low intensity laser acupoint irradiation on inhibiting islet beta-cell apoptosis in rats with type 2 diabetes
    Guoxin Xiong, Leilei Xiong, Xinzhong Li
    Laser Physics.2016; 26(9): 095605.     CrossRef
  • Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea
    Elisabet Martínez-Ceron, Isabel Fernández-Navarro, Francisco Garcia-Rio
    Sleep Medicine Reviews.2016; 25: 121.     CrossRef
  • Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase III trial
    S. Hong, C.‐Y. Park, K. A. Han, C. H. Chung, B. J. Ku, H. C. Jang, C. W. Ahn, M.‐K. Lee, M. K. Moon, H. S. Son, C. B. Lee, Y.‐W. Cho, S.‐W. Park
    Diabetes, Obesity and Metabolism.2016; 18(5): 528.     CrossRef
  • Senp2 expression was induced by chronic glucose stimulation in INS1 cells, and it was required for the associated induction of Ccnd1 and Mafa
    Hye Seung Jung, Yu Mi Kang, Ho Seon Park, Byung Yong Ahn, Hakmo Lee, Min Joo Kim, Jin Young Jang, Sun-Whe Kim
    Islets.2016; 8(6): 207.     CrossRef
  • ANTIDIABETIC EVALUATION OF CHONEMORPHA MACROPHYLLA ROOTS BY IN VIVO METHODS USING MALE WISTAR ALBINO RATS AND ITS MECHANISM OF ACTION
    K. R. Krishna Kumar, K. K. Srinivasan
    INDIAN DRUGS.2016; 53(12): 42.     CrossRef
  • Comparative gene expression profiles in pancreatic islets associated with agouti yellow mutation and PACAP overexpression in mice
    Kazuya Ikeda, Shuhei Tomimoto, Soken Tsuchiya, Ken-ichi Hamagami, Norihito Shintani, Yukihiko Sugimoto, Atsushi Ichikawa, Atsushi Kasai, Takanobu Nakazawa, Kazuki Nagayasu, Atsuko Hayata-Takano, Akemichi Baba, Hitoshi Hashimoto
    Biochemistry and Biophysics Reports.2015; 2: 179.     CrossRef
  • Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes
    LI-XUE GUAN, HUI GUAN, HAI-BO LI, CUI-AI REN, LIN LIU, JIN-JIN CHU, LONG-JUN DAI
    Experimental and Therapeutic Medicine.2015; 9(5): 1623.     CrossRef
  • p13 overexpression in pancreatic β-cells ameliorates type 2 diabetes in high-fat-fed mice
    Shintaro Higashi, Kazuhiko Katagi, Norihito Shintani, Kazuya Ikeda, Yukihiko Sugimoto, Soken Tsuchiya, Naoki Inoue, Shota Tanaka, Mai Koumoto, Atsushi Kasai, Takanobu Nakazawa, Atsuko Hayata-Takano, Ken-Ichi Hamagami, Shuhei Tomimoto, Takuya Yoshida, Tada
    Biochemical and Biophysical Research Communications.2015; 461(4): 612.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal